ACT-001 got FDA Orphan Drug Designation

Glioblastoma multiforme (GBM)  new medicine ACT-001 got FDA Orphan drug designation on 8^th Nov, but still need to wait approved for orphan indication.  In the phase I clinical trials in Australia, the result is better than TEMODAR(Temozolomide). The new medicine is applied by Accendatech USA Incorporated and also for Acute Myeloid Leukemia. 

BonHoa Pharmacy will pay constant attention on the development of ACT-001. For more Glioblastoma Multiforme (GBM) medicine please visit us.